Genmont Biotech Inc.

Genmont Biotech Incorporation

Li-Jin Hsu

Wan-Hua Tsai

Wen-Ling Yeh

Ming-Shiou Jan

Yi-Hsing Chen

I-ling Hsu

Yen-Wan Hsiao

Ying-Chun Lai

Wee-wei Chieng

Shan-ju Hsu

Junko Sugawara

A probiotic composition for improving an effect of a chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer is disclosed in the present disclosure. The probiotic composition comprises an effective amount ofGMNL-133, an effective amount ofGMNL-89, and a pharmaceutically acceptable carrier, wherein theGMNL-133 was deposited in the China Center for Type Culture Collection on Sep. 26, 2011 under an accession number CCTCC NO. M 2011331, and theGMNL-89 was deposited in the China Center for Type Culture Collection on Nov. 19, 2007 under an accession number CCTCC NO. M 207154. A method for improving the effect of the chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer is further disclosed in the present disclosure.

Method for improving an effect of chemotherapeutic drug of gemcitabine on inhibiting pancreatic cancer and improving side effect of chemotherapeutic drug of Gemcitabine

The present invention relates to a probiotic composition for preventing, improving or alleviating pancreatic cancer and a method for preventing, improving or alleviating the pancreatic cancer and its complications using the probiotic composition. The probiotic composition, which is consisted of specific strains and specific ratio ofto, can significantly improve or alleviate various symptomatic indicators and severity of pancreatic cancer, thereby being applied on a method for preventing, improving or alleviating the pancreatic cancer and its complications using an oral composition including thestrains.

Probiotic composition for preventing, improving or alleviating pancreatic cancer and application thereof

Growing community of inventors

Tainan, Taiwan

Li-Jin Hsu